5. IKKε was found to be upregulated aberrantly in breast cancer,6 ovarian cancer,7 and GBM.3, 8, 9 Therefore, IKKε inhibition is a desirable GBM therapeutic strategy as evidenced by abundance of researches.10, 11, 12 For example, Liu et al reported that a selective inhibitor of IKKε (Amlexanox) had anticancer effect in human GBM cell lines.5 Another study showed that IKKε silence contributed to proliferation‐ and invasion‐inhibition of GBM cells.13 Collectively, these data strongly support the role of IKKε in tumorigenesis. Here, IKBKE is linked to ovarian cancer.